Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Ir O P Catalyst. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Novel synthesis method offers high enantioselectivity and significant cost reduction for chiral catalyst manufacturing supply chains globally ensuring reliable pharmaceutical intermediates
Patent CN114524701B reveals a novel chiral phosphoric acid catalyzed synthesis of N-N axis chiral pyrroles with high enantioselectivity and cytotoxic activity.
Novel chiral phosphoric acid catalyzed synthesis of N-N axis pyrroles. High yield, mild conditions, scalable for pharma intermediates.
Patent CN114160206B reveals a novel chiral copper catalyst enabling high-yield, enantioselective synthesis of indole pharmaceutical intermediates with superior purity.
Patent CN113980044B details a novel Ir-O-P catalyzed C-H borylation method offering high yields and broad substrate scope for pharmaceutical intermediates.
Novel chiral phosphoric acid catalyzed resolution method for axially chiral oxindole-substituted styrenes. High ee values up to 96%. Ideal for pharma intermediates.
This patent introduces a novel axial chiral naphthalene-pyrrole phosphine catalyst with mild reaction conditions and high enantioselectivity, enabling cost-effective production of chiral intermediates for pharmaceutical applications.
Breakthrough axial chiral catalyst enables high-purity API intermediates with enhanced stereoselectivity and scalable manufacturing advantages.
Discover a scalable, cost-effective synthesis method for indolocyclopentane compounds with >95% yield and 93% ee. Ideal for pharmaceutical R&D and production of prostate cancer therapeutics.
Discover N-N axis chiral indole-pyrrole synthesis with 97% ee, reducing R&D costs and supply chain risks for asymmetric pharmaceutical catalysts.
Solve supply chain risks in chiral synthesis with this novel protonic acid catalyst. Achieve 98% ee and 96% yield in ruthenium-catalyzed reactions. Contact us for custom synthesis.
Discover how this novel axial chiral phosphine catalyst enables high-yield, high-enantioselective synthesis for pharmaceutical intermediates, reducing production costs and supply chain risks.
Discover how N-heterocyclic carbine catalysis enables high-yield, enantioselective synthesis of spiro hydroxyindole pentamethylene beta-lactones for drug development and insecticide production.
Discover a cost-effective, air-stable synthesis for trifluoromethyl 1,2,4-triazine compounds. Eliminate heavy metal catalysts and nitrogen protection, ensuring supply chain reliability for your API production.
Solve high catalyst loading issues in asymmetric hydrogenation. Our CDMO expertise delivers 99% yield, 97% ee at 0.02 mol% catalyst for chiral APIs and flavors.